Allogene Therapeutics, INC 10-Q quarterly reports

Allogene Therapeutics announced a leadership transition with Zachary Roberts appointed as President and CEO, effective July 1, 2026, while also providing updates on its ongoing clinical programs, including ALPHA3 and ALLO-316.

Allogene Therapeutics reports reduced net losses and significant clinical advancements for its CAR T programs, while managing a workforce reduction and ongoing capital needs.

Allogene Therapeutics reported a reduced net loss in Q2 2025, extended its cash runway into late 2027, and advanced key clinical programs while discontinuing a lymphodepletion agent due to a serious adverse event.

Allogene Therapeutics amends its strategic collaboration with Foresight Diagnostics and updates its non-employee director compensation policy, as detailed in its latest 10-Q filing.

Allogene Therapeutics reports a net loss of $66.3 million for Q3 2024, focusing on core programs and advancing clinical trials.

Allogene Therapeutics reports a net loss of $66.4 million for the second quarter of 2024, while focusing on key clinical programs and expanding its licensed territory.

Allogene Therapeutics reported a net loss of $65 million for Q1 2024, while focusing on key clinical programs and expanding its license for CD19 products to Europe and the UK.